← SynDRA
TAFENOQUINE
SynDRA canonical compound SYN0002382 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Mechanism of action | antimalarial agent |
|---|
| Indication | malaria |
|---|
| Disease area | infectious disease |
|---|
All known targets
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SLC6A3
- SLC6A2
- PTGS1
- PGR
- DRD3
- ACHE
- HTR1A
- SLC6A4
- PDE4A
- PDE3A
- OPRM1
- MAOA
- HTR2B
- HRH3
- ADORA1
- HDAC6
- F2
- ESR1
- DRD1
- CHRM2
- CHRM1
- AR
- ALB
- ADRA2A
- ADRA1A
- TBXA2R
Drug classes
- Anti-Infective Agents
- Antimalarials
- Antiparasitic Agents
- Antiprotozoal Agents
- antimalarial agent
ATC classes
Cross-references
Synonyms
- ARAKODA
- Arakoda
- KRINTAFEL
- Kodatef
- Krintafel
- arakoda
- krintafel
- tafenoquine succinate
- Tafenoquina
- SB-252263-AAB
- WR-238605
- WR 238605
- Etaquine
- WR238605
- Tafenoquine [INN:BAN
- tafenoquina
- tafenoquinum
- RefChem:57195
- DTXCID50817448
- P01BA07
- CHEBI:135752
- MFCD00598712
- Tafenoquine (USAN)
- TAFENOQUINE [USAN]
- Tafenoquine free base
- C24H28F3N3O3
- SB-252263
- UNII-262P8GS9L9
- Tafenoquine [USAN:INN:BAN]
- Tafenoquine?
- TAFENOQUINE [MI]
- TAFENOQUINE [INN]
- TAFENOQUINE [MART.]
- TAFENOQUINE [WHO-DD]
- SCHEMBL347388
- GTPL9722
- orb1708413
- SCHEMBL29450724
Reported adverse events
- Hypersensitivity
- Anxiety
- Dizziness
- Headache
- Nausea
- Vomiting
- Abnormal dreams
- Back pain
- Depression
- Gastrointestinal disorder
- Insomnia
- Motion sickness
Look up TAFENOQUINE in the interactive SynDRA portal →